JCOVDEN

This brand name is authorized in Estonia, Spain, France, Japan, Netherlands, Poland, Tunisia, South Africa

Active ingredients

The drug JCOVDEN contains one active pharmaceutical ingredient (API):

1 COVID-19 Vaccine Janssen UNII B6L4N5Z4GH - SARS-COV-2

SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is a monovalent vaccine composed of a recombinant, replicationincompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 full-length spike (S) glycoprotein in a stabilised conformation. Following administration, the S glycoprotein of SARSCoV-2 is transiently expressed, stimulating both neutralising and other functional S-specific antibodies, as well as cellular immune responses directed against the S antigen, which may contribute to protection against COVID-19. Read about SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S)

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JCOVDEN Suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BN02		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1842319, 1845558
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201525001
Country: FR	Base de données publique des médicaments	Identifier(s): 64798803
Country: JP	医薬品医療機器総合機構	Identifier(s): 631341HA1023
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100449317
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 1527305EP
Country: ZA	Health Products Regulatory Authority	Identifier(s): 55/30.5/0849